Bardhan K D, Müller-Lissner S, Bigard M A, Bianchi Porro G, Ponce J, Hosie J, Scott M, Weir D G, Gillon K R, Peacock R A, Fulton C
Rotherham General Hospitals NHS Trust, Rotherham S60 2UD.
BMJ. 1999 Feb 20;318(7182):502-7. doi: 10.1136/bmj.318.7182.502.
To assess intermittent treatment over 12 months in patients with symptomatic gastro-oesophageal reflux disease.
Randomised, multicentre, double blind, controlled study. Patients with heartburn and normal endoscopy results or mild erosive changes received omeprazole 10 mg or 20 mg daily or ranitidine 150 mg twice daily for 2 weeks. Patients remaining symptomatic had omeprazole 10 mg or ranitidine dose doubled for another 2 weeks while omeprazole 20 mg was continued for 2 weeks. Patients who were symptomatic or mildly symptomatic were followed up for 12 months. Recurrences of moderate or severe heartburn during follow up were treated with the dose which was successful for initial symptom control.
Hospitals and primary care practices between 1994 and 1996.
677 patients with gastro-oesophageal reflux disease.
Total time off active treatment, time to failure of intermittent treatment, and outcomes ranked from best to worst.
704 patients were randomised, 677 were eligible for analyses; 318 reached the end of the study with intermittent treatment without recourse to maintenance antisecretory drugs. The median number of days off active treatment during follow up was 142 for the entire study (281 for the 526 patients who reached a treatment related end point). Thus, about half the patients did not require treatment for at least 6 months, and this was similar in all three treatment groups. According to outcome, 378 (72%) patients were in the best outcome ranks (no relapse or one (or more) relapse but in remission until 12 months); 630 (93%) had three or fewer relapses in the intermittent treatment phase. Omeprazole 20 mg provided faster relief of heartburn. The results were similar in patients with erosive and non-erosive disease.
Intermittent treatment is effective in managing symptoms of heartburn in half of patients with uncomplicated gastro-oesophageal reflux disease. It is simple and applicable in general practice, where most patients are seen.
评估有症状的胃食管反流病患者进行为期12个月的间歇性治疗效果。
随机、多中心、双盲、对照研究。有烧心症状且内镜检查结果正常或有轻度糜烂性改变的患者,接受每日10毫克或20毫克奥美拉唑治疗,或每日两次、每次150毫克雷尼替丁治疗,为期2周。仍有症状的患者,将奥美拉唑剂量增至10毫克或将雷尼替丁剂量加倍,再治疗2周,而20毫克奥美拉唑组继续治疗2周。有症状或症状较轻的患者随访12个月。随访期间中度或重度烧心复发的患者,采用最初控制症状成功的剂量进行治疗。
1994年至1996年期间的医院和基层医疗诊所。
677例胃食管反流病患者。
停止积极治疗的总时间、间歇性治疗失败的时间,以及按最佳到最差排序的治疗结果。
704例患者被随机分组,677例符合分析条件;318例患者在未使用维持性抑酸药物的情况下完成了间歇性治疗并结束研究。在整个研究中,随访期间停止积极治疗的天数中位数为142天(在达到与治疗相关终点的526例患者中为281天)。因此,约一半患者至少6个月无需治疗,这在所有三个治疗组中相似。根据治疗结果,378例(72%)患者治疗结果最佳(无复发或有一次(或多次)复发但在12个月内缓解);630例(93%)患者在间歇性治疗阶段复发次数为三次或更少。20毫克奥美拉唑缓解烧心症状更快。糜烂性和非糜烂性疾病患者的结果相似。
间歇性治疗对半数无并发症的胃食管反流病患者的烧心症状有效。该方法简单,适用于大多数患者就诊的全科医疗。